TY - JOUR
T1 - The diagnostic performance of classical molecular tests used for detecting human papillomavirus
AU - Munoz, Marina
AU - Camargo, Milena
AU - Soto-De Leon, Sara C.
AU - Rojas-Villarraga, Adriana
AU - Sanchez, Ricardo
AU - Jaimes, Camilo
AU - Perez-Prados, Antonio
AU - Patarroyo, Manuel E.
AU - Patarroyo, Manuel A.
N1 - Funding Information:
We would like to extend our sincerest gratitude to Asociación Investigación Solidaria SADAR , Caja Navarra (CAN) (Navarra, Spain) and Agencia Española de Cooperación Internacional para el Desarrollo (AECID) (Project 08-CAP2-0609) for supporting and financing this project. We would like to extend our sincerest gratitude to the SIPLAS laboratory for the HC2 assays and thank Cindy Lancheros, Rocio Meneses and Duby Botero for their technical support and Jason Garry for revising this manuscript. Appendix A
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/10
Y1 - 2012/10
N2 - Cervical samples were evaluated for human papillomavirus (HPV) presence using the hybrid capture-2 (HC2) assay and the polymerase chain reaction (PCR) with three different primer sets (GP5+/6+, MY09/11 and pU1M/2R). PCR results were compared to HC2 and results of all assays were compared to cytological and colposcopy findings. Post-test probability was assessed in individual assays and test combinations. HPV-DNA prevalence was 36.5% with HC2 and 55.2% with PCR. MY09/11 detected HPV-DNA in 38% of samples, GP5+/6+ in 19.1% and pU1M/2R in 16.4%. pU1M/2R and HC2 had the highest concordance (75.31%, k= 0.39 in the whole population; 74.1%, k= 0.5 in women with abnormal cytology). pU1M/2R had the best diagnostic performance, including optimal post-test probabilities and cervical abnormality detection (individually or in a panel of tests). Women positive for pU1M/2R may be at higher risk of disease progression; the assay performance when combined with a Pap smear in cervical cancer screening programs should be evaluated.
AB - Cervical samples were evaluated for human papillomavirus (HPV) presence using the hybrid capture-2 (HC2) assay and the polymerase chain reaction (PCR) with three different primer sets (GP5+/6+, MY09/11 and pU1M/2R). PCR results were compared to HC2 and results of all assays were compared to cytological and colposcopy findings. Post-test probability was assessed in individual assays and test combinations. HPV-DNA prevalence was 36.5% with HC2 and 55.2% with PCR. MY09/11 detected HPV-DNA in 38% of samples, GP5+/6+ in 19.1% and pU1M/2R in 16.4%. pU1M/2R and HC2 had the highest concordance (75.31%, k= 0.39 in the whole population; 74.1%, k= 0.5 in women with abnormal cytology). pU1M/2R had the best diagnostic performance, including optimal post-test probabilities and cervical abnormality detection (individually or in a panel of tests). Women positive for pU1M/2R may be at higher risk of disease progression; the assay performance when combined with a Pap smear in cervical cancer screening programs should be evaluated.
UR - http://www.scopus.com/inward/record.url?scp=84864324188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864324188&partnerID=8YFLogxK
U2 - 10.1016/j.jviromet.2012.05.023
DO - 10.1016/j.jviromet.2012.05.023
M3 - Article
C2 - 22659023
AN - SCOPUS:84864324188
SN - 0166-0934
VL - 185
SP - 32
EP - 38
JO - Journal of Virological Methods
JF - Journal of Virological Methods
IS - 1
ER -
